Gatell, J. M., Assoumou, L., Moyle, G., Waters, L., Johnson, M., Domingo Pedrol, P., . . . Pozniak, A. L. (2017). Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.
Citación estilo ChicagoGatell, José Mª|||0000-0002-4705-3244, et al. Switching From a Ritonavir-boosted Protease Inhibitor to a Dolutegravir-based Regimen for Maintenance of HIV Viral Suppression in Patients With High Cardiovascular Risk. 2017.
Cita MLAGatell, José Mª|||0000-0002-4705-3244, et al. Switching From a Ritonavir-boosted Protease Inhibitor to a Dolutegravir-based Regimen for Maintenance of HIV Viral Suppression in Patients With High Cardiovascular Risk. 2017.